Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View Plans2-year trend showing gross, operating, and net profit margins
Sanofi India's net profit margin of 20.4% in FY2024 reflects excellent profitability, with operating margin at 23.2% and gross margin at 51.8%.
In FY 2024, Sanofi India posted a gross margin of 51.8%, an operating margin of 23.2%, a net margin of 20.4%. Gross Margin = (Revenue - COGS) / Revenue; Operating Margin = EBIT / Revenue; Net Margin = Net Income / Revenue. Typical healthy ranges: Gross 20-40%, Operating 10-20%, Net 5-10%+. Consistent or improving margins indicate strong competitive positioning.
2-year trend showing revenue, gross profit, and net profit
Sanofi India's revenue declined 30.4% to 20.30B in FY2024, with net profit also falling 31.4% to 4.13B.
In FY 2024, Sanofi India's revenue declined by 30.4% year-over-year. Revenue is total income from operations. Gross Profit is revenue minus cost of goods. Net Profit is the bottom line after all expenses. Consistent growth across all three signals a healthy, expanding business.
2-year trend showing shareholder returns
Sanofi India's ROE of 48.0% in FY2024 indicates excellent capital efficiency.
In FY 2024, Sanofi India reported an ROE of 48.0%. ROE = (Net Income / Shareholders' Equity) x 100. Measures how efficiently the company turns equity into profit. Above 15% is generally strong; above 25% is excellent. Very high ROE may signal high leverage — check alongside debt levels.
2-year trend comparing profitability with cash generation
Sanofi India's FCF/NI ratio of 1.03x in FY2024 indicates solid earnings quality with FCF tracking net income.
In FY 2024, Sanofi India's free cash flow exceeded net income. Free Cash Flow = Operating Cash Flow - Capital Expenditure. When FCF exceeds net income, it suggests high-quality, cash-backed earnings. Persistent gaps may indicate aggressive accounting or heavy capex needs.
2-year trend comparing profitability with cash from operations
Sanofi India's OCF/NI ratio of 1.12x in FY2024 indicates sound cash management with earnings well-backed by cash.
In FY 2024, Sanofi India's operating cash flow exceeded net income. Operating Cash Flow is the actual cash from core operations. OCF exceeding net income signals strong cash collection. OCF trailing net income may indicate aggressive revenue recognition or working capital issues.
Measure a company's financial leverage, liquidity, and ability to meet financial obligations.
2-year trend showing short-term liquidity position
Sanofi India's current ratio of 1.57x in FY2024 indicates healthy short-term liquidity.
In FY 2024, Sanofi India reported a current ratio of 1.57. Current Ratio = Current Assets / Current Liabilities. Measures short-term liquidity. A ratio of 1.5-3.0 is generally healthy; below 1.0 signals liquidity risk; above 3.0 may indicate underutilized assets.
2-year trend showing ability to service debt
Sanofi India's interest coverage ratio of 313.7x in FY2024 indicates comfortable debt servicing capacity.
In FY 2024, Sanofi India reported an interest coverage ratio of 313.7x. Interest Coverage = EBIT / Interest Expense. Shows how many times operating profit covers interest payments. Above 5x is comfortable; below 1.5x signals potential difficulty servicing debt.
2-year trend showing financial leverage and capital structure
Sanofi India's debt-to-equity ratio of 0.02x in FY2024 reflects a conservative, low-leverage capital structure.
In FY 2024, Sanofi India reported a debt-to-equity ratio of 0.02. Debt-to-Equity = Total Debt / Total Equity. Below 1.0 is conservative; 1.0-2.0 is moderate; above 2.0 indicates higher financial risk. Capital-intensive industries naturally carry higher ratios.
2-year trend showing total debt with year-over-year changes
Sanofi India's debt increased 1.6% YoY in FY2024 — debt levels are increasing.
In FY 2024, Sanofi India's total debt increased by 1.6% year-over-year. Total Debt includes short-term debt, long-term loans, debentures, and capital leases. YoY changes (shown as percentages) reveal whether the company is leveraging up or deleveraging.
Year-over-year change in diluted shares outstanding
Sanofi India's diluted shares remained virtually unchanged in FY2024.
Over 2 years (FY2023–FY2024), diluted shares remained essentially unchanged at 23.03M.
In FY 2024, Sanofi India's diluted shares decreased by 0.0% year-over-year. Diluted Shares accounts for stock options, warrants, and convertibles. Positive YoY change means dilution (red); negative means buybacks (green). Consistent dilution above 5% annually is a red flag.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2024